调肝理脾方联合替吉奥胶囊治疗晚期原发性肝癌患者的临床观察  

Clinical observation of Tiaoganlipi decoction combined with S-1 capsule in the treatment of advanced primary liver cancer patients

作　　者：杜卫星[1] 叶青[1] 李金科[1] 谭华炳[1] 胡波[1] 汪晓[1] 雷志雄[1] 曹玲[1] 

机构地区：[1]湖北医药学院附属人民医院感染性疾病科,湖北十堰442000

出　　处：《中国中西医结合消化杂志》2017年第5期340-343,共4页Chinese Journal of Integrated Traditional and Western Medicine on Digestion

基　　金：基金项目:湖北省重大科学技术成果(No:十科鉴字[2013]第65号)

摘　　要：[目的]探讨调肝理脾方联合替吉奥胶囊治疗晚期原发性肝癌患者的临床效果。[方法]采用回顾性研究方法,2011年2月~2014年8月选择在我院诊治的晚期原发性肝癌患者98例作为研究对象,根据治疗方法的不同分为中药组60例与常规组38例,常规组给予基于替吉奥胶囊的化疗方案治疗,中药组在常规组治疗的基础上给予调肝理脾方治疗,记录与随访2组近远期预后情况。[结果]中药组与常规组的治疗总有效率分别为66.7%和42.1%,中药组的治疗总有效率明显高于常规组(P<0.05)。2组毒副反应主要为血液毒性反应、肝肾功能异常、消化道反应、神经系统反应等,2组毒副反应情况比较差异无统计学意义(P>0.05)。治疗后中药组与常规组的KPS评分分别为(78.13±4.24)分和(69.14±5.10)分,都明显高于治疗前的(57.24±6.19)分和(58.14±7.30)分(P<0.05),且治疗后中药组的KPS评分明显高于常规组(P<0.05)。中药组的6个月与1年生存率分别为91.7%和66.7%,都明显高于常规组的71.1%和50.0%(P<0.05)。[结论]调肝理脾方联合替吉奥胶囊治疗晚期原发性肝癌患者能提高治疗疗效,不增加毒副反应的发生,改善临床功能症状,延长远期生存时间,有很好的应用价值。[Objective]To investigate the clinical effect of Tiaoganlipi decoction combined with S-1 cap- sule in the treatment of advanced primary liver cancer patients. [Methods]From February 2011 to August 2014,98 patients with advanced primary liver cancer in our hospital for treatment were selected as the research object,all the patients were divided into 2 groups according to the different treatment methods,Chinese medicine group of 60 patients and 38 patients of normal group. The normal group was treated with chemotherapy of S-1, while the Chinese medicine group was added Tiaoganlipi treatment based on the treatment in control group. Recent and long-term prognosis was recorded. [Results] The total effective rate of the Chinese medicine group and the normal group were 66.7% and 42.1% respectively,and the total effec- tive rate of the Chinese medicine group was significantly higher than that of the normal group（P〈0.05） . The toxicity of the two groups were mainly in the blood toxicity,liver and kidney function abnormalities, gastrointestinal reactions, nervous system reactions. The two groups of adverse reactions were not signifi- cantly different（P〉0.05）. After the treatment,KPS scores in the Chinese medicine group and the normal group were 78.13±4.24 points and 69.14±5.10 points,which were significantly higher than that before treatment of 57.24±6.19 points and 58.14±7.30 points（P〈0.05） ,and the KPS score in the Chinesemedicine group after treatment was significantly higher than the control group（P〈0.05）. The 6 months and 1 year survival rates of the traditional Chinese medicine group were 91.7% and 66.7% ,respectively, which were significantly higher than those of the normal group of 71.1% and 50.0M（P〈0.05）. [Conclusion]Tiaoganlipi decoction combined with S-1 capsule in the treatment of advanced primary liver cancer pa- tients can improve the curative effect. It does not increase the side reaction, can improve the clinical symp- toms of function, prolong the survival time of the long

关 键 词：调肝理脾方 替吉奥胶囊 晚期原发性肝癌 毒副反应 生存率 

分 类 号：R735.7[医药卫生—肿瘤]